Next Science (ASX:NXS) has announced the publication of a study it says demonstrates the efficacy of XPERIENCE in decreasing periprosthetic joint infection (PJI) following a Total Knee Arthroplasty (TKA).
Next Science is a medical technology company focused on commercialising its XBIO suite of products to reduce the impact of biofilm-based infections on human health.
Dr Ronald W. Singer's study, 'Real World Evidence of the Impact of a Novel Surgical Irrigant on Surgical Site Infections in Primary Total Knee Arthroplasty Performed at an Ambulatory Surgery Center,' has been published in the Journal of Surgical Infections.
The primary objective of the retrospective study was to evaluate the impact of Next Science's advanced surgical irrigation product, XPERIENCE, on surgical site infections (SSI) in primary TKA performed at an ambulatory surgery centre.
Among the 524 primary TKA surgeries, one instance of PJI was diagnosed within 90 days of index surgery, which was attributed to an exogenously acquired upper respiratory tract infection. The 0.19 per cent PJI incidence rate indicated significant efficacy of XPERIENCE in decreasing PJI, said Next Science.
Dr Singer concluded that XPERIENCE is a "promising intraoperative antimicrobial irrigant that can be easily incorporated into a broader infection prevention strategy".
Next Science's CEO and Managing Director I.V. Hall said, "The study by leading orthopaedic surgeon Dr Ronald Singer shows that the use of XPERIENCE can improve patient outcomes by reducing infection when used in Total Knee Arthroplasty procedures.
"The results have been through a peer review process and their publication in the Journal of Surgical Infections adds to our growing body of clinical evidence for XPERIENCE and leads to broader recognition in the Orthopaedic community. We will continue to work closely with surgeons to conduct clinical research that further investigates the effectiveness of Next Science's products."
